Spots Global Cancer Trial Database for lde225
Every month we try and update this database with for lde225 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis | NCT02151864 | Hepatocellular ... Cirrhosis | LDE225 | 18 Years - | University of California, San Diego | |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | NCT01125800 | Medulloblastoma Rhabdomyosarcom... Neuroblastoma Hepatoblastoma Glioma Astrocytoma | LDE225 | 12 Months - 18 Years | Novartis | |
| Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy | NCT01456676 | Philadelphia Ch... | Nilotinib + LDE... | 18 Years - | Novartis | |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | NCT02182622 | Prostate Cancer | Docetaxel Prednisone LDE225 | 18 Years - | Hackensack Meridian Health | |
| Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients | NCT01769768 | Advanced Solid ... | LDE225 Wafarin Bupropion | 18 Years - | Novartis | |
| LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | NCT02182622 | Prostate Cancer | Docetaxel Prednisone LDE225 | 18 Years - | Hackensack Meridian Health | |
| Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | NCT00880308 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients | NCT01487785 | Pancreatic Canc... | LDE225+gemcitab... | 18 Years - | Novartis | |
| LDE225 for Patients With PTCH1 or SMO Mutated Tumors | NCT02002689 | PTCH1 or SMO Ac... | LDE225 | 18 Years - | Novartis | |
| A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | NCT01327053 | Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | NCT00880308 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| LDE225 for Patients With PTCH1 or SMO Mutated Tumors | NCT02002689 | PTCH1 or SMO Ac... | LDE225 | 18 Years - | Novartis | |
| Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer | NCT02195973 | Recurrent Ovari... | LDE225 | 19 Years - | University of Alabama at Birmingham | |
| Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | NCT02254551 | Multiple Myelom... | LDE225 Bortezomib | 18 Years - | SCRI Development Innovations, LLC | |
| Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | NCT01350115 | Basal Cell Carc... Gorlin Syndrome Nevoid Basal Ce... | LDE225 Placebo | 18 Years - | Novartis | |
| An East Asian Study of LDE225 | NCT01208831 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | NCT01431794 | Pancreatic Duct... | LDE225-600mg Gemcitabine nab-paclitaxel LDE225-400mg LDE225-800mg | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | NCT02358161 | Pancreatic Canc... | gemcitabine and... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients | NCT02027376 | Advanced Breast... | LDE225 Docetaxel | 18 Years - | Spanish Breast Cancer Research Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
